Marshall on Oncology

 
 

  • Practice-Changing Regorafenib Data at 2018 GI Cancers Symposium   Dr John Marshall discusses new science in pancreatic and colorectal cancers, presented at the 2018 Gastrointestinal Cancers Symposium.
  • Celebrating the End of Chemo Can Isolate Those Not So Lucky   Dr John Marshall on how a recent symposium opened his eyes to the unintended effects of a bell-ringing ceremony at his practice.
  • New GI Cancer Studies: Curious Failures, Hidden Gems   Dr John Marshall on recent publications, both positive and negative, that may change your practice.
  • Clinical Trials Are 'Too Damn Complicated'   Simplifying clinical research is possible and desirable, says Dr John Marshall.
  • Will Adjuvant Oxaliplatin Data Change Practice in CRC?   Dr John Marshall previews the GI cancer studies being presented at ASCO with his picks for the ones to watch, and predicts that a plenary presentation may be practice-changing.
  • Mud Pies: Superfood for the Microbiome?   Too much cleanliness and sanitizing might reduce the effectiveness of our immune system, which could be a contributing cause of illness.
  • 12 Chemo Cycles: More Toxicity Than Therapy?   Dr John Marshall suggests that 12 cycles of chemotherapy in metastatic colorectal cancer exceeds what is needed for maximum tumor regression and often results in toxicity that is better avoided.
  • 'Can Do' Collaborations Speed Progress in GI Cancers   Dr John Marshall reports on two initiatives that harness the collective efforts of advocacy groups, academic researchers, and industry to advance research in GI cancers.
  • HER2+ Colorectal Cancer: Slicing the Pie Into Curable Portions   Dr John Marshall views a study of dual targeting in HER2+ CRC as an argument for combining broad molecular testing and precision medicine to slice the cancer pie into curable portions.
  • CRC Builds Up STEAM in Midst of Blizzard   After digging out from a blizzard, Dr John Marshall discusses highlights from GICS 2016, including molecular testing, new drugs, and key studies results, plus the STEAM trial in colorectal cancer.
  • Can Physicians Help Heal the Body Politic?   Troubled by news reports of growing violence worldwide, Dr John Marshall asks: What can healthcare providers do to cool feverish minds and heal the body politic?
  • Is Chemo Needed in Patients With MSI Colon Cancer?   FOLFOX is standard treatment for stage III colorectal cancer. But for tumors with high microsatellite instability, adjuvant chemotherapy might not be necessary, says Dr John Marshall.
  • ASCO 2015 Raises the Question of Value   Dr John Marshall puts his vacation on hold to highlight the themes of ASCO 2015, including the critical question: What is value in cancer care, and how much is riding on the correct answer?
  • Waves of Emotion, Understanding After PBS Cancer   Dr John Marshall asks clinicians to be mindful of the emotional response cancer patients will have to the PBS Cancer documentary--and to use heightened public awareness to push for research funding.
  • Is 'Conflict of Interest' Hampering Cancer Research?   Dr John Marshall discusses how the current requirements for declaring conflict of interest are complicating cancer research and possibly barring the best minds from working together.
  • Coverage Cut-off for Cancer Costs?   Will US and European guidelines follow the UK's lead and incorporate value metrics in their recommendations? Dr. John Marshall, reporting on a discussion at GICS, says it's only a matter of time.
  • Immuno Death Ray to GI Cancers   Can immunotherapy 'clip the force field' of gastrointestinal tumors? Dr John Marshall and experts say yes and will discuss advances during the Ruesch Symposium 2014, December 5, Washington, DC.
  • Longer Life, at Any Cost?   Dr John Marshall asks his cancer patients on their first visit: How long do you want to live? Their answers have implications for the practice of oncology -- and the healthcare system as a whole.
  • Cologuard: Breakthrough in CRC Screening   Dr. John Marshall discusses Cologuard, a new screening test for colorectal cancer that can detect CRC missed by colonoscopy, which he hopes will keep masses of patients out of his office.
  • Why Don't CRC Survival Data Add Up?   Dr. John Marshall questions why the survival rate in a large phase 3 trial presented at ASCO was nearly double the survival rates achieved by earlier trials while using the same medicines.